2026-10-28T02:56:27Zhttps://kostu-rdlopen.rawdatalibrary.net/oai/request

oai:kostu-rdlopen.rawdatalibrary.net:kostu/106542026-10-27T23:53:23Zopenairedrivercom_kostu_10000col_kostu_10001com_kostu_10007col_kostu_10059

Tamoxifen-Based Dimers: Design, Synthesis, Cell Viability Evaluation on Breast Cancer Cells, and Computational InsightsErtugrul, BerrakAytatli, AbdulmelikKaratas, Omer FarukEssiz, SelcukAksakal, FatmaSaracoglu, Nurullahbreast cancerdensity functional theorydimeric compoundsdrug resistancemolecular dockingselective estrogen receptor modulators (SERMs)tamoxifenTamoxifen (TMX) resistance presents a significant challenge in the treatment of ER+ breast cancer. In this study, four novel tamoxifen-based dimers were synthesized and evaluated for their antitumor activities. Among these, (Z,Z)-1 exhibited potent antiproliferative effects in ER+ cells, demonstrating selective toxicity toward cancer cells over normal cells. (Z,Z)-1 significantly outperformed tamoxifen with IC50 values of 9.18 μM (24 h) and 6.86 μM (48 h) against MCF-7 cells. Additionally, it showed greater selectivity toward ER+ breast cancer cells compared with both triple-negative cancer cells and non-cancerous cells. Mechanistic studies indicated that (Z,Z)-1 induces apoptosis in MCF-7 cells through a cell-cycle-independent mechanism, unlike TMX, which arrests cells at the G0/G1 phase. These findings suggest that (Z,Z)-1 may be a promising candidate for further development as an alternative to tamoxifen therapy in ER+ breast cancer treatment. The docking studies revealed that (Z,Z)-1 exhibits the strong binding affinity to ERα, highlighting its potential as a promising therapeutic candidate for ER+ breast cancer treatment.John Wiley and Sons Inc2026Articlehttps://rdlopen.rawdatalibrary.net/r/kostu/10654https://doi.org/10.1002/ardp.702600365-6233enArchiv der Pharmazieinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://kostu-rdlopen.rawdatalibrary.net/tr/items/kostu/10654